BVAXFBioVaxys Technology Corp.

About BioVaxys Technology Corp. (BVAXF)

BioVaxys Technology Corp. (BVAXF) is a Biotechnology company headquartered in Etobicoke, ON, Canada whose shares trade over-the-counter on the OTCQB tier.

BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on its DPX™ immune-educating technology platform and its HapTenix© "neoantigen" tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological diseases. DPX™ is a patented antigen delivery platform that can incorporate a range of bioactive molecules to produce targeted, long-lasting immune responses enabled by various formulated components. The DPX platform facilitates antigen delivery to regional lymph nodes and has been demonstrated to induce robust and durable T cell and B cell responses in pre-clinical and clinical studies for both cancer and infectious disease.

Products and services

The Company's clinical stage pipeline includes maveropepimut-S (MVP-S), based on the DPX™ platform, and is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer.BioVaxys is also developing DPX™+SurMAGE, a, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX™-RSV for Respiratory Syncytial Virus, DPX™+peanut antigen for peanut allergy prophylaxis, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© "neoantigen" tumor cell construct platform targeting ovarian cancer.

BVAXF key facts

Ticker symbol

BVAXF

Market tier

OTCQB

Sector

Healthcare

Industry

Biotechnology

Headquarters

Etobicoke, ON, Canada

Country of incorporation

CA

Year of incorporation

2018

Employees

6

Estimated market cap

$9.64M (as of Apr 9, 2025)

Shares outstanding

292,225,203

Reporting standard

International Reporting: Canadian Securities Exchange

Audit status

Audited

Fiscal year end

10/31

Latest filing

Quarterly Report (Jul 31, 2024)

BioVaxys Technology Corp. leadership

• James Passin — CEO
• Kenneth Kovan — COO, President
• Christopher Padraig Cherry — CFO
• David Berd MD — Chief Med. Officer
• Janet Elizabeth Francis — Other
• Annika Tilley — Other
• Franchesca Del-Barrio Alcanse — Other

Explore more: Biotechnology stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with B